Hepatitis B surface antigenemia in blood donors following vaccination
- PMID: 7770897
- DOI: 10.1046/j.1537-2995.1995.35695288765.x
Hepatitis B surface antigenemia in blood donors following vaccination
Abstract
Background: Detection of hepatitis B surface antigen (HBsAg) in recently vaccinated adults has not previously been reported. Transient detectable HBsAg has been observed in newborn infants immunized with a recombinant hepatitis B vaccine.
Study design and methods: Over a 1-year period, eight HBsAg-positive blood donors mentioned during donor notification that they had been vaccinated for hepatitis B virus 1 to 3 days before donation. Follow-up tests for HBsAg, antibodies to HBsAg, and antibodies to hepatitis B core antigen were performed 3 to 37 weeks after immunization. Four months later, a group of 19 donors who were coworkers received hepatitis B vaccination and then donated blood the next day. The coworkers were observed for duration of antigenemia.
Results: A total of nine cases of transient, confirmed (neutralizable) antigenemia occurred in healthy individuals who donated blood 1 to 3 days following vaccination with a recombinant hepatitis B vaccine. Follow-up testing showed no evidence of infection by hepatitis B virus. One (5.3%) of 19 blood donors vaccinated as a group had antigenemia at Day 1 but not on Days 2 and 3 following immunization.
Conclusion: Individuals recently vaccinated for hepatitis B may test positive for HBsAg and become permanently disqualified as blood donors. Therefore, blood collection centers should consider temporary deferral of potential donors who recently received hepatitis B vaccine.
Comment in
-
Temporary deferral of blood donors after administration of hepatitis B vaccine.Transfusion. 1997 Aug;37(8):880. doi: 10.1046/j.1537-2995.1997.37897424417.x. Transfusion. 1997. PMID: 9280339 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
